Leviliv Injection contains Levetiracetam 500 mg, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, which is believed to inhibit abnormal neuronal firing and reduce seizure activity. This injectable formulation is intended for intravenous administration, providing rapid onset of action in patients unable to take oral medication or requiring immediate seizure control. Leviliv Injection is typically used as adjunctive therapy in adults and pediatric patients aged 4 years and older. The dosage should be individualized based on clinical response and tolerability, with careful monitoring for adverse effects such as somnolence, dizziness, fatigue, and behavioral symptoms including irritability or mood changes. Caution is advised in patients with renal impairment, necessitating dose adjustment. Leviliv Injection should be administered under medical supervision, ensuring appropriate hydration and monitoring for hypersensitivity reactions. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any component of the formulation. This medication should be used as part of a comprehensive epilepsy management plan, with regular follow-up to assess efficacy and safety.